Please check your internet connection and try again.
# Tamsulosin
## Overview
Tamsulosin is an alpha-1 adrenergic receptor antagonist selective for alpha-1A and alpha-1D receptors found in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra.
## Primary Indications
* Benign Prostatic Hyperplasia (BPH)
## Adult Dosing
* **BPH:** 0.4 mg orally once daily.
* **Maximum:** 0.8 mg orally once daily.
* Dosing may be initiated at 0.4 mg, with an increase to 0.8 mg after 2-4 weeks if needed.
## Pediatric Dosing
* Tamsulosin is **not indicated** for use in the pediatric population.
## Dose Adjustments
* No specific dose adjustments are recommended for renal or hepatic impairment based on available data, though caution is advised in severe impairment.
## Contraindications
* Hypersensitivity to tamsulosin or any component of the formulation.
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (e.g., retrograde ejaculation, ejaculatory duct obstruction), rhinitis, decreased libido.
* **Serious:** Hypotension, syncope, angioedema, intraoperative floppy iris syndrome (IFIS) during cataract surgery.
## Key Drug Interactions
* **CYP3A4 inhibitors (e.g., ketoconazole, ritonavir):** May increase tamsulosin exposure; use with caution.
* **Alpha-blockers:** Additive hypotensive effects.
* **Antihypertensives:** Increased risk of hypotension.
## Monitoring
* Blood pressure, especially with concomitant antihypertensives.
* Symptoms of BPH.
* Signs of hypersensitivity reactions.
## Clinical Pearls
* Take tamsulosin at the same time each day, preferably in the morning.
* Tamsulosin can cause dizziness and affects the ability to operate machinery or drive. Advise patients to sit or lie down upon experiencing dizziness or lightheadedness.
* Inform ophthalmologists of tamsulosin use prior to cataract surgery due to the risk of IFIS.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols before making clinical decisions.*
